We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.
- Authors
Perrin, Richard J; Craig-Schapiro, Rebecca; Malone, James P; Shah, Aarti R; Gilmore, Petra; Davis, Alan E; Roe, Catherine M; Peskind, Elaine R; Li, Ge; Galasko, Douglas R; Clark, Christopher M; Quinn, Joseph F; Kaye, Jeffrey A; Morris, John C; Holtzman, David M; Townsend, R Reid; Fagan, Anne M
- Abstract
Ideally, disease modifying therapies for Alzheimer disease (AD) will be applied during the 'preclinical' stage (pathology present with cognition intact) before severe neuronal damage occurs, or upon recognizing very mild cognitive impairment. Developing and judiciously administering such therapies will require biomarker panels to identify early AD pathology, classify disease stage, monitor pathological progression, and predict cognitive decline. To discover such biomarkers, we measured AD-associated changes in the cerebrospinal fluid (CSF) proteome.
- Publication
PloS one, 2011, Vol 6, Issue 1, pe16032
- ISSN
1932-6203
- Publication type
Journal Article
- DOI
10.1371/journal.pone.0016032